9 Meters Biopharma Inc (NMTR) USD0.001
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease. Its pipeline includes NM-002, Larazotide, NM-003, NM-004, NM-102 and NM-004. NM-002 is a long-acting injectable GLP-1 analogue for short bowel syndrome (SBS). Larazotide is an orally administered, gut-restricted tight-junction regulator for celiac disease. NM-003 is a GLP-2 analogue, under orphan indication selection. NM -004 is an immunomodulator, granted pediatric orphan designation in ulcerative colitis. NM-102, a small molecule peptide, is being developed as a potential microbiome modulator and undergoing an indication selection process. NM-004 is patent-protected and has orphan designation for pediatric ulcerative colitis.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.